Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignancies  

作　　者：Michael J Ricci Jeffrey A Medin Ronan S Foley 

机构地区：[1]Department of Pathology and Molecular Medicine,McMaster University [2]University Health Network Toronto,Ontario M5G 2M1,Canada [3]Juravinski Hospital and Cancer Center,711 Con-cession Street

出　　处：《World Journal of Stem Cells》2014年第4期380-390,共11页世界干细胞杂志（英文版）（电子版）

摘　　要：Allogeneic bone marrow transplant is a life-saving procedure for adults and children that have high-risk or relapsed hematological malignancies. Incremental advances in the procedure, as well as expanded sources of donor hematopoietic cell grafts have significantly improved overall rates of success. Yet, the outcomes for patients for whom suitable donors cannot be found remain a significant limitation. These patients may benefit from a hematopoietic cell transplant wherein a relative donor is fully haplotype mismatched. Previously this procedure was limited by graft rejection, lethal graft-versus-host disease, and increased treatmentrelated toxicity. Recent approaches in haplo-identical transplantation have demonstrated significantly improved outcomes. Based on years of incremental preclinical research into this unique form of bone marrow transplant, a range of approaches have now been studied in patients in relatively large phase Ⅱ trials that will be summarized in this review.Allogeneic bone marrow transplant is a life-saving procedure for adults and children that have high-risk or relapsed hematological malignancies. Incremental advances in the procedure, as well as expanded sources of donor hematopoietic cell grafts have significantly improved overall rates of success. Yet, the outcomes for patients for whom suitable donors cannot be found remain a significant limitation. These patients may benefit from a hematopoietic cell transplant wherein a relative donor is fully haplotype mismatched. Previously this procedure was limited by graft rejection, lethal graft-versus-host disease, and increased treatmentrelated toxicity. Recent approaches in haplo-identical transplantation have demonstrated significantly improved outcomes. Based on years of incremental preclinical research into this unique form of bone marrow transplant, a range of approaches have now been studied in patients in relatively large phase Ⅱ trials that will be summarized in this review.

关 键 词：Peripheral blood progenitors Stem cell transplantation GRAFT-VERSUS-HOST disease Haplo-identical DONOR HEMATOLOGICAL MALIGNANCIES 

分 类 号：R733[医药卫生—肿瘤]